The Alabama Supreme Court recently sided with a plaintiff seeking damages against a grocery store pharmacy for injuries she suffered after she was given the wrong prescription. Defense counsel in Morgan v. Publix Super Markets Inc. argued in their motion for summary judgment before the Jefferson Circuit Court that the plaintiff failed to make her case because she hadn’t produced an expert witness that would have established a breach of the applicable standard of care under the Alabama Medical Liability Act. However, in reversing the trial court’s earlier decision to grant that motion, the Alabama Supreme Court found that a pharmacy’s negligence in dispensing the wrong medication is so straightforward that the plaintiff didn’t need the testimony of an expert witness to prove it.Read More
Our Tuscaloosa defective medical device lawyers know transvaginal mesh products were sold by manufacturers with lots of promises to doctors and patients that the surgical mesh would make it easier to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). For thousands of women who began to experience complications after their TVM surgeries, however, the surgical mesh turned out not to live up to its promises. Now, a new study has demonstrated that transvaginal mesh is not only unsafe but also that it is ineffective. The study was conducted by Georgetown University and published in the September issue of Obstetrics and Gynecology. The results are alarming and every patient who has had a mesh procedure or who is considering one should be aware of what the research showed.Read More
The first case in a series of multidistrict transvaginal mesh lawsuits against the manufacturer C.R. Bard did not go as the company had hoped. As a result, the health care products manufacturer intends to appeal, knowing full well that such a judgment sets the tone for the flood of future cases that are waiting in the pipeline. However, a federal judge has denied a motion from the defendant Bard to stay or hold the other pending cases while this one works its way through the appellate process. In the case of Cisson v. C.R. Bard, the jury sided with the plaintiff, awarding her $250,000 in compensatory damages and $1.75 million in punitive damages.Read More
It’s been several months since compounding pharmacies in New England came under severe scrutiny by health officials, following a fatal outbreak of fungal meningitis that affected patients nationwide. Our Alabama pharmaceutical litigation attorneys predicted that, given the lack of oversight, such hazards were sure to repeat. Sure enough, they have – this time at a Texas compounding facility called NuVision Pharmacy. The U.S. Food and Drug Administration has issued a second warning regarding the facility’s supposedly sterile products, which the company has refused to recall, despite the FDA’s mandate. The first warning about the company’s products was issued back in mid-May.Read More
Contaminated steroid injections blamed for at least 32 deaths in 19 states have led federal investigators to sterility problems at a second New England drugmaking facility. Ameridose is one of the leading suppliers of pre-filled syringes and is now under fire in a widening probe into dangerous drugs that have put thousands of patients at risk. Alabama pharmaceutical attorneys understand the widening probe into activities at Ameridose means the risks may be far from over. Ameridose agreed to shut down for inspection in October after its sister company, the New England Compounding Center, was blamed for distributing steroid injections containing fungal meningitis to health clinics nationwide. USA Today reported this week that the head of the Food and Drug Administration will ask lawmakers to grant the agency more authority to oversee such compounding facilities. Congress is racing through hearings and calling for legislation so there is now little doubt reforms will be enacted. However, as Reuter News reports, Congress has known about the risks posed to consumers by such facilities for a number of years. In 2007, it killed the Safe Drug Compounding Act sponsored by the late Senator Ted Kennedy amid heavy lobbying from the pharmaceutical industry.Read More
Drug maker GlaxoSmithKline PLC said Thursday that it has agreed in principle with the United States government on a $3 billion settlement of investigations of the company’s sales and marketing practices. The agreement is expected to be completed next year, and the settlement will be paid through the company’s cash resources, it said. The case dates from 2004, and included investigations of possible price irregularities and the development and marketing of the diabetes drug Avandia. The company said the tentative settlement covers both civil and criminal liabilities.Read More
"I am a practicing lawyer who has from time to time referred clients and litigation cases to Cross & Smith for handling. Without exception, the effort and attention to detail by these attorneys have been incredible. I think that is what sets them apart - they leave no stone unturned in their diligent pursuit of justice and fair compensation to those cheated, injured or killed. I highly recommend these guys."